Penny stocks are a great way to make quick money, but they aren’t for the faint of heart. Whether it’s something to do with global headlines or company-specific catalysts, there are countless ways to make money with penny stocks. Knowing how to trade them and use data to your advantage can pay off handsomely. Today we not only look at a handful of penny stocks with news but also stocks under $1. This is where the fun can start because even a slight move (up or down) can spark a significant percentage change. Let’s look at some of these companies, and you can decide if the risk is worth the potential reward.
Penny Stocks To Buy For Under $1
- ProQR Therapeutics (NASDAQ: PRQR)
- Cybin Inc. (NYSE: CYBN)
- Statera Biopharma Inc. (NASDAQ: STAB)
- Exela Technologies Inc. (NASDAQ: XELA)
- Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN)
- Artelo Biosciences Inc. (NASDAQ: ARTL)
- Meten Holding Group Ltd. (NASDAQ: METX)
How To Buy Penny Stocks?
To buy penny stocks, you’ll first need a broker that allows you access to stocks under $5. You’ll also want to know which exchange the companies on your penny stocks list trade on. If they’re NASDAQ or NYSE stocks, most brokers should allow access. However, if you’re looking at some of the cheapest penny stocks to buy, you’re likely watching those trading Over The Counter (OTC). Once you’ve figured that out, buying penny stocks isn’t a difficult task. You’d fund the account, navigate to the trading execution page, and hit the “buy” button. With that in mind, are any of these penny stocks under $1 on the buy or sell side of your watch list today?
[Read More] Hot Penny Stocks to Buy Now? 3 to Watch in Early July
Penny Stocks To Buy For Under $1: ProQR Therapeutics (NASDAQ: PRQR)
One of the exciting areas of the stock market right now is the biotech industry. Even if the broader trend is downward, you’re likely to find at least a few biotech penny stocks on the move.
Why Is PRQR Stock Moving?
Since the company develops RNA therapies, it has been in the spotlight since the onset of the pandemic. Companies like Moderna have shed more light on RNA – or mRNA – treatment platforms. ProQR gave an update on its sepofarsen program after a post-hoc analysis of Phase 2/3 Illuminate trial data in patients with inherited retinal disease. ProQR also buttoned up a strategic review made to extend the company’s runway and execute on its goal to build out its RNA platform for conditions with “high unmet” needs.
[Read More] 3 Penny Stocks That Turned $1,000 Into Over $9,300 This Quarter
Upcoming catalysts? As far as any upcoming events to keep track of, ProQR said it plans to meet with the EMA and FDA next quarter to discuss data from the Illuminate trial. There’s also an upcoming Retinal Cell and Gene Therapy Summit at the end of April and the Association for Research in Vision and Ophthalmology at the beginning of May. ProQR presents Illuminate trial data at both of these events.
2. Cybin Inc. (NYSE: CYBN)
Magic mushroom stocks have quietly carved out a niche in the stock market. While some attempted to put these in the same category of marijuana stocks, science seems to have designated it much differently. Cybin Inc. is one of the magic mushroom stocks and, trading below $1, is one of the lowest-priced names in the industry.
Why Is CYBN Stock Moving?
This week, Cybin announced new data on its CYB004 inhaled treatment candidate for therapeutic psychedelic delivery. “CYB004 via inhalation may solve these challenges and support a clinical path forward for this important therapeutic. As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians,” said Doug Drysdale, Chief Executive Officer of Cybin.
What’s on the horizon? Cybin also outlined plans for a regulatory filing submission in a pilot study this quarter. It also expects the begin the study next quarter.
3. Statera Biopharma Inc. (NASDAQ: STAB)
Another one of the hot penny stocks moving pre-market is Statera Biopharma. The company specializes in immune treatments pertaining to immune restoration. Its pipeline includes a platform of toll-like receptor agonists. Statera uses its program to develop candidates for treating Crohn’s disease, hematology, pancreatic cancer, and even COVID-19.
[Read More] Penny Stocks To Buy Now According To These 4 Analysts In June 2022
Why Is STAB Stock Moving?
Wednesday, Statera entered into an agreement with Coeptis Therapeutics (OTC: COEP). The deal will see Statera give Coeptis the right to acquire Statera’s TLR5 platform being developed as an acute radiation syndrome treatment. Statera receives $6 million and revenue-based milestones.
4. Exela Technologies Inc. (NASDAQ: XELA)
Biotech isn’t the only “tech” on the radar right now. Exela Technologies is a prime example as it’s on the watch list thanks to tech-related news. Exela specializes in business process technologies, including automation, communications, and information management.
Why Is XELA Stock Moving?
Exela announced a new customer and contract valued at $6.8 million over the next three years. Its Exchange for Bills and Payments (XBP) platform will be utilized by unnamed “newly acquired customers.”
Recent excitement began buzzing around XELA stock after the company decided to cancel a pending reverse stock split in addition to adding mobile to its suite of payment solutions with Global Bank earlier this month.
5. Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN)
Drug therapeutics company Sonnet BioTherapeutics is developing a pipeline of immunotherapeutic drugs targeting solid tumors. Shares of SONN stock surged last month thanks to FDA clearance of Sonnet’s first human trial for solid tumor candidate, SON-1010.
Why Is SONN Stock Moving?
SONN stock is back on the watch list after another critical headline this week. Sonnet announced dosing the first patient in a Phase 1 trial of SON-1010. This study is designed to form the basis for possible combinations with other immunotherapies, among other things.
6. Artelo Biosciences Inc. (NASDAQ: ARTL)
Sticking with the biotech trend in the stock market today, Artelo Biosciences is popping in premarket trading. The company is developing treatments for people suffering from cancers, pain, and neurological conditions. Artelo’s treatment platform targets everything from PTSD and inflammation to anorexia and cancer.
Why Is ARTL Stock Moving?
Wednesday’s jump in ARTL stock can be traced back to its premarket news headlines. Artelo reported positive preclinical results for its ART27.13 in patients with cancer-related anorexia.
“These exciting early results demonstrate that ART27.13 is capable of reducing negative effects of chemicals produced by multiple cancers on human muscle fibers…We look forward to seeing how these results may translate into the ongoing CAReS study currently in the final stages of enrolling cohort 3 at six clinical trial sites in the United Kingdom and Ireland.”
Saoirse O’Sullivan, Ph.D., Vice President Translational Science, Artelo Biosciences
This was a big focus of the company earlier this year. Artelo released an update in January highlighting its anticipated acceleration in clinical development for ART27.13 following a classification change in the U.K., where it was no longer considered a Schedule 1 controlled substance.
7. Meten Holding Group Ltd. (NASDAQ: METX)
Metaverse stocks are becoming a reality for investors. Whether it’s Norwegian Cruise Line launching NFTs or apparel companies building out their own metaverse, the industry is captivating attention this year. Meten Holding specializes in workplace training. However, it has been actively developing metaverse, blockchain, and cryptocurrency mining businesses recently.
Why Is METX Stock Moving?
This week, Meten Holding provided an update on its metaverse vocational education courses. The company launched a trial of its metaverse vocational education courses in December. With rising COVID cases in China, the company is anticipating growth potential in the near term. CEO Alan Peng also explained that the company “will continue to launch the Courses in major cities in China, once the number of COVID-19 cases decline sufficiently. We expect to achieve a gross billing of RMB50 million (approximately US$7.86 million ) from the Courses in the full year 2022, with the goal of cultivating 2000 visual design talents.”
Final Thoughts About Penny Stocks
Whether you’re talking about Apple (NASDAQ: AAPL) or emerging growth stocks under $5, the goal is the same. Make money and repeat the process. While this sounds easy, a lot goes into trading penny stocks and managing risk. Here are a few articles to check out if you’re brand new to the stocks market:
